公开(公告)号：WO2004035737A2

公开(公告)日：2004-04-29

申请号：PCT/US0332510

申请日：2003-10-14

Applicant: UNIV TENNESSEE RES FOUNDATION ,  DALTON JAMES T ,  MILLER DUANE D

Inventor： DALTON JAMES T ,  MILLER DUANE D

IPC: C07D213/75 ,  C07D213/84 ,  C07K14/72 ,  C12N

CPC classification number: C07D213/75 ,  C07D213/84 ,  C07K14/721

Abstract: This invention provides a class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). Several of the SARM compounds have been found to have an unexpected androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. Other SARM compounds have been found to have an unexpected antiandrogenic activity of a nonsteroidal ligand for the androgen receptor. The SARM compounds, either alone or as a composition, are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of acute and/or chronic muscular wasting conditions; e) preventing and/or treating dry eye conditions; f) oral androgen replacement therapy; g) decreasing the incidence of, halting or causing a regression of prostate cancer; and/or h) inducing apoptosis in a cancer cell.

Abstract translation: 本发明提供一类雄激素受体靶向剂（ARTA）。 这些药剂定义了一种新的化合物亚类，它们是选择性雄激素受体调节剂（SARM）。 已经发现几种SARM化合物对雄激素受体具有非甾类化合物的意想不到的雄激素和合成代谢活性。 已经发现其他SARM化合物对雄激素受体具有非甾类配体的意想不到的抗雄激素活性。 SARM化合物，单独或作为组合物，可用于a）男性避孕; b）治疗各种激素相关病症，例如与老年雄性雄激素降低有关的病症（ADAM），如疲劳，抑郁，性欲降低，性功能障碍，勃起功能障碍，性腺机能减退，骨质疏松症，脱发，贫血， 肥胖，肌营养不良，骨质减少，骨质疏松症，良性前列腺增生，情绪和认知和前列腺癌的改变; c）治疗与男性雄激素降低相关的病症（ADIF），如性功能障碍，性欲降低，性腺机能减退，肌营养不良，骨质减少，骨质疏松症，认知和情绪改变，抑郁症，贫血，脱发，肥胖，子宫内膜异位症，乳腺癌 癌症，子宫癌和卵巢癌; d）治疗和/或预防急性和/或慢性肌肉消瘦病症; e）预防和/或治疗干眼症状; f）口服雄激素替代疗法; g）降低前列腺癌的发生率，停止或导致消退; 和/或h）诱导癌细胞中的细胞凋亡。

公开(公告)号：WO2004007685A2

公开(公告)日：2004-01-22

申请号：PCT/US0322050

申请日：2003-07-14

Applicant: UNIV TENNESSEE RES FOUNDATION

Inventor： JENNINGS LISA K ,  LONGHURST CELIA M ,  COOK GEORGE A ,  BAO JIANXONG ,  ZHANG CHUNXIANG ,  WHITE MELANIE M ,  CROSSNO JOSEPH T JR ,  LU YI

IPC: C07K14/705 ,  C07K16/28 ,  C12N

CPC classification number: C07K16/2896 ,  A61K2039/505 ,  C07K14/70596 ,  C07K2317/34

Abstract: Polypeptide and peptide fragments of CD9 as well as antibodies raised against those fragments of CD9. Uses of polypeptide and peptide fragments of CD9, antibodies, and inhibitors of CD9-related kinases include modifying cell behavior such as adhesion, motility, proliferation, survival, cell spreading, invasiveness, pericellular FN matrix assembly, and cell-to-cell interaction.

Abstract translation: CD9的多肽和肽片段以及针对这些CD9片段产生的抗体。 CD9的多肽和肽片段，抗体和CD9相关激酶抑制剂的用途包括修饰细胞行为，例如粘附，运动性，增殖，存活，细胞扩散，侵袭性，周细胞FN基质组装和细胞与细胞相互作用。

公开(公告)号：WO2015157655A3

公开(公告)日：2016-05-12

申请号：PCT/US2015025341

申请日：2015-04-10

Applicant: UNIV TENNESSEE RES FOUNDATION

Inventor： PFEFFER LAWRENCE M ,  GARNER JO MEAGAN

IPC: C12Q1/68 ,  C07K16/26 ,  G01N33/53

CPC classification number: G01N33/74 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/57438 ,  G01N2800/52

Abstract: The presently disclosed subject matter involves methods of predicting response in a subject to treatment for a disease with a VEGF targeted therapeutic, and for evaluating and/or monitoring treatment for a disease involving use of a VEGF targeted therapeutic in a subject. Such methods involve determining a level of ANGPTL4 expression in a biological sample from the subject; and comparing the level of ANGPTL4 expression in the sample with a reference, wherein the subject is predicted to be a likely responder or non-responder based on the ANGPTL4 expression in the sample relative to the reference. Administering a VEGF targeted therapeutic to the subject is initiated or continued when the subject is predicted to be a likely responder.

Abstract translation: 目前公开的主题涉及预测受试者对具有VEGF靶向治疗的疾病的治疗的反应的方法，以及用于评估和/或监测涉及在受试者中使用VEGF靶向治疗的疾病的治疗。 这些方法涉及确定来自受试者的生物样品中ANGPTL4表达的水平; 并将样本中ANGPTL4表达水平与参考值进行比较，其中基于相对于参考样本的ANGPTL4表达，预测受试者是可能的应答者或非应答者。 当预测受试者是可能的应答者时，开始或继续对受试者施用VEGF靶向治疗。

公开(公告)号：WO2015023773A3

公开(公告)日：2015-10-29

申请号：PCT/US2014050928

申请日：2014-08-13

Applicant: UNIV TENNESSEE RES FOUNDATION ,  HONG LIANG

Inventor： HONG LIANG

IPC: A61K33/00 ,  A61K9/58 ,  A61K33/42 ,  A61Q11/00

CPC classification number: A61K8/736 ,  A61K8/025 ,  A61K8/11 ,  A61K8/19 ,  A61K8/24 ,  A61K31/722 ,  A61K2800/412 ,  A61K2800/413 ,  A61K2800/592 ,  A61K2800/74 ,  A61Q11/00

Abstract: Tooth remineralization compositions are provided for preventing and treating tooth decay and dental erosion in a patient. The composition comprises a remineralizing agent encapsulated in a polymer. In various embodiments, the remineralizing agent may be in a polymeric chitosan microspheres and/or nanospheres and the remineralizing agent comprises calcium and/or phosphate. Methods of preparation and use of the remineralization compositions are also disclosed.

Abstract translation: 提供牙齿再矿化组合物用于预防和治疗患者的龋齿和牙齿侵蚀。 该组合物包含包封在聚合物中的再矿化剂。 在各种实施方案中，再矿化剂可以在聚合壳聚糖微球和/或纳米球中，并且再矿化剂包含钙和/或磷酸盐。 还公开了制备和使用再矿化组合物的方法。

公开(公告)号：WO2015066630A9

公开(公告)日：2015-07-09

申请号：PCT/US2014063724

申请日：2014-11-03

Applicant: UNIV TENNESSEE RES FOUNDATION

Inventor： QI MING ,  ZAWODZINSKI THOMAS ,  FOISTER SHANE

IPC: B82B3/00 ,  B82Y30/00 ,  B82Y40/00

CPC classification number: H01M4/9008 ,  B82Y30/00 ,  B82Y40/00 ,  H01M4/8615 ,  H01M4/8626 ,  H01M4/8647 ,  H01M4/8652 ,  H01M4/8657 ,  H01M4/88 ,  H01M4/8871 ,  H01M4/8892 ,  H01M4/90 ,  H01M4/9041 ,  H01M4/9075 ,  H01M4/92 ,  H01M12/02 ,  H01M12/06 ,  H01M12/08 ,  H01M12/085 ,  H01M2004/021 ,  H01M2300/0014 ,  H01M2300/0068 ,  Y02E60/128

Abstract: A catalyst is provided for the two electron reduction of oxygen. The catalyst can be reversible or near-reversible. The catalyst comprises a gold and a cobalt coordination complex, i.e., N,N'-bis(salicylidene)ethylene- diaminocobalt (II) (cobalt salen) or a derivative thereof. The cobalt coordination complex can be polymerized to form a film, for example, via electropolymerization, to cover a gold surface. Also provided are metal-air batteries, fuel cells, and air electrodes that comprise the catalyst, as well as methods of using the catalyst, for example, to reduce oxygen and/or produce hydrogen peroxide.

Abstract translation: 提供了用于氧的两次电子还原的催化剂。 催化剂可以是可逆的或近似可逆的。 催化剂包括金和钴配位络合物，即N，N'-双（亚水杨基）乙烯 - 二氨基钴（II）（钴salen）或其衍生物。 钴配位络合物可以聚合形成膜，例如通过电聚合来覆盖金表面。 还提供了包含催化剂的金属空气电池，燃料电池和空气电极，以及使用催化剂例如减少氧气和/或产生过氧化氢的方法。

公开(公告)号：WO2012054284A3

公开(公告)日：2012-07-05

申请号：PCT/US2011056063

申请日：2011-10-13

Applicant: UNIV TENNESSEE RES FOUNDATION ,  PFEFFER LAWRENCE ,  FAN MEIYUN ,  PFEFFER SUSAN R ,  HANDORF CHARLES

Inventor： PFEFFER LAWRENCE ,  FAN MEIYUN ,  PFEFFER SUSAN R ,  HANDORF CHARLES

IPC: C12Q1/68 ,  G01N33/53

CPC classification number: G01N33/6866 ,  C12Q1/6883 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158

Abstract: The present invention is a method and kit for determining responsiveness of a subject to treatment with a Type I interferon based upon the expression of gene signatures shown to be stimulated by interferon. A method for testing the propensity of a test compound to induce a Type I interferon response is also provided.

Abstract translation: 本发明是一种用于根据显示被干扰素刺激的基因特征的表达来确定受试者与I型干扰素治疗的反应性的方法和试剂盒。 还提供了测试化合物诱导I型干扰素应答倾向的方法。

公开(公告)号：WO2011103540A2

公开(公告)日：2011-08-25

申请号：PCT/US2011025634

申请日：2011-02-22

Applicant: UT BATTELLE LLC ,  UNIV TENNESSEE RES FOUNDATION ,  VIRGINIA MUSEUM OF NATURAL HISTORY FOUNDATION ,  BLENCOE JAMES G ,  ANOVITZ LAWRENCE M ,  PALMER DONALD A ,  BEARD JAMES S

Inventor： BLENCOE JAMES G ,  ANOVITZ LAWRENCE M ,  PALMER DONALD A ,  BEARD JAMES S

CPC classification number: C01F5/24 ,  B01D2251/402 ,  B01D2256/22 ,  C01B32/60 ,  C01D7/00

Abstract: A process of producing magnesium metal includes providing magnesium carbonate, and reacting the magnesium carbonate to produce a magnesium-containing compound and carbon dioxide. The magnesium-containing compound is reacted to produce magnesium metal. The carbon dioxide is used as a reactant in a second process. In another embodiment of the process, a magnesium silicate is reacted with a caustic material to produce magnesium hydroxide. The magnesium hydroxide is reacted with a source of carbon dioxide to produce magnesium carbonate. The magnesium carbonate is reacted to produce a magnesium-containing compound and carbon dioxide. The magnesium-containing compound is reacted to produce magnesium metal. The invention also relates to the magnesium metal produced by the processes described herein.

Abstract translation: 生产金属镁的方法包括提供碳酸镁，并且使碳酸镁反应以产生含镁化合物和二氧化碳。 含镁化合物反应生成金属镁。 二氧化碳在第二过程中用作反应物。 在该方法的另一个实施方案中，硅酸镁与苛性物质反应生成氢氧化镁。 氢氧化镁与二氧化碳源反应生成碳酸镁。 碳酸镁反应生成含镁化合物和二氧化碳。 含镁化合物反应生成金属镁。 本发明还涉及通过本文所述的方法生产的镁金属。

公开(公告)号：WO2010123607A9

公开(公告)日：2010-12-16

申请号：PCT/US2010022556

申请日：2010-01-29

Applicant: UNIV TENNESSEE RES FOUNDATION ,  DENG SUXIANG ,  HASSAN MOHAMMAD K ,  MAURITZ KENNETH A ,  MAYS JIMMY W ,  GIDO SAMUEL P

Inventor： DENG SUXIANG ,  HASSAN MOHAMMAD K ,  MAURITZ KENNETH A ,  MAYS JIMMY W ,  GIDO SAMUEL P

IPC: C08F297/04 ,  C08F36/02 ,  C08F299/00 ,  C08G65/48 ,  C08J3/24

CPC classification number: C08C19/12 ,  C08C19/18 ,  C08F8/00 ,  C08F8/36 ,  C08F2810/20 ,  C08F2810/30 ,  C08J5/2268 ,  C08J2325/10 ,  H01M8/0289 ,  H01M8/1025 ,  C08F32/06 ,  C08F8/42 ,  C08F112/08 ,  C08F8/20 ,  C08F212/12 ,  C08F232/06 ,  C08F297/04 ,  C08F297/046 ,  C08F8/34 ,  C08F132/06 ,  C08F8/44

Abstract: Materials prepared from polydienes, such as poly(cyclohexadiene), and hydrophilic polymers, such as poly(alkylene oxide), are described. Methods of making the materials and their use in fuel cell membranes, batteries, breathable chemical-biological protective materials, and templates for sol-gel polymerization are also provided. The materials can be crosslinked and sulfonated, and can include copolymers and polymer blends.

Abstract translation: 描述了由聚二烯如聚（环己二烯）和亲水性聚合物如聚（烯化氧）制备的材料。 还提供了制造这些材料的方法及其在燃料电池膜，电池，透气化学 - 生物防护材料以及用于溶胶 - 凝胶聚合的模板中的用途。 这些材料可以被交联和磺化，并且可以包括共聚物和聚合物共混物。

公开(公告)号：WO2009108388A8

公开(公告)日：2010-07-01

申请号：PCT/US2009001324

申请日：2009-03-02

Applicant: UNIV TENNESSEE RES FOUNDATION

Inventor： SLOMINSKI ANDRZEJ ,  LI WEI ,  ZBYTEK BLAZEJ ,  TUCKEY ROBERT C ,  ZJAWIONY JORDAN K ,  NGUYEN MINH NGOC ,  ZMIJEWSKL MICHAL A ,  JANJETOVIC ZORICA ,  SWEATMAN TREVOR W ,  MILLER DUANE D ,  CHEN JIANJUN

IPC: A61K8/63 ,  A61P35/00 ,  C07J3/00 ,  C07J11/00

CPC classification number: C07C401/00 ,  A61K8/63 ,  A61K2800/81 ,  A61K2800/94 ,  A61Q19/00 ,  C07J3/00 ,  C07J11/00 ,  C12P7/02

Abstract: Provided herein are steroidal compounds that are androsta-5,7-dienes or a pregna-5,7-dienes and ultraviolet B (UVB) conversion products thereof which includes pharmaceutical compositions of the steroidal compounds. Also provided is a method for producing hydroxylated metabolites of cholecalciferol via the P450scc (CYPl IA 1) or CYP27B 1 enzyme systems and the hydroxylated metabolites so produced. In addition, a method for inhibiting proliferation of either a normally or abnormally proliferating cell by contacting the cell with any of the compounds described herein. A related method is provided of treating a condition associated with the proliferating cell such as a cancer, a skin disorder, a defect in cell differentiation, cosmetic, prophylaxsis, or healthy cell maintenance.

Abstract translation: 本文提供的甾族化合物是雄激素-5,7-二烯或其前体-5,7-二烯和紫外线B（UVB）转化产物，其包括甾体化合物的药物组合物。 还提供了通过P450scc（CYP119A）或CYP27B1酶系统和如此制备的羟基化代谢产物来产生胆钙化甾醇的羟基化代谢物的方法。 此外，通过使细胞与本文所述的任何化合物接触来抑制正常或异常增殖细胞增殖的方法。 提供了一种相关方法来治疗与增殖细胞相关的病症，例如癌症，皮肤病症，细胞分化缺陷，化妆品，预防或健康细胞维持。

公开(公告)号：WO2009002372A3

公开(公告)日：2009-08-20

申请号：PCT/US2008003928

申请日：2008-03-26

Applicant: UNIV TENNESSEE RES FOUNDATION

Inventor： FLECKENSTEIN JAMES M

IPC: A61K38/16 ,  A61P31/04 ,  A61P37/00

CPC classification number: A61K39/0258 ,  A61K2039/543 ,  A61K2039/55594

Abstract: The present invention describes a novel mechanism of adhesion by flagellated Gram-negative bacteria such as enterotoxigenic Escherichia coli (ETEC), where the bacteria secretes a protein, EtpA which binds to the conserved region of the flagellin protein located at the tip of the flagella. The present invention also discloses that EtpA-mediated interaction and intestinal colonization require interaction with flagellin. Also disclosed herein is a vaccine composition that can be used for either active or passive immunization of mammals for the prevention or treatment of infections caused by flagellated Gram-negative bacteria.

Abstract translation: 本发明描述了通过鞭状革兰氏阴性菌如肠致毒性大肠杆菌（ETEC）粘附的新型机制，其中细菌分泌蛋白质，EtpA结合位于鞭毛尖端的鞭毛蛋白的保守区域。 本发明还公开了EtpA介导的相互作用和肠定植需要与鞭毛蛋白相互作用。 本文还公开了疫苗组合物，其可用于哺乳动物的活性或被动免疫以预防或治疗由鞭毛革兰氏阴性细菌引起的感染。